# VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]

Source: https://onco.cc/trials/nct06264180/  
OnCo record `nct06264180` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Vusolimogene oderparepvec, Nivolumab, Relatlimab + nivolumab and Pembrolizumab in Advanced melanoma, run by Replimune, Inc., now recruiting.

## Summary

VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3] is a phase 3 interventional study registered as NCT06264180 by Replimune, Inc., with 400 participants planned, started 2024-07-11 and due to reach its primary completion in 2030-09-30. Interventions recorded: Vusolimogene Oderparepvec, Nivolumab, Nivolumab + Relatlimab, Pembrolizumab, Single-agent chemotherapy. Conditions recorded: Advanced Melanoma.

Linked to the drug Vusolimogene oderparepvec because the registry names it among its interventions and Advanced melanoma among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06264180
- Phase: 3
- Setting: Randomized, Ph3 Clinical Study Comparing Vusolimogene Oderparepvec in Combination With Nivolumab Vs Treatment of Physician's Choice in Patients With Advanced Melanoma That Progressed on Anti-PD-1 and Anti-CTLA-4 Containing Treatment [IGNYTE-3]
- Sponsor: Replimune, Inc.
- Enrolled: 400

## Sources

- ClinicalTrials.gov NCT06264180: https://clinicaltrials.gov/study/NCT06264180

## Connected records

- cancers: [Advanced melanoma (unresectable stage III and stage IV)](https://onco.cc/cancers/advanced-melanoma/)
- drugs: [Nivolumab](https://onco.cc/drugs/nivolumab/), [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/), [Relatlimab + nivolumab](https://onco.cc/drugs/relatlimab-nivolumab/), [Vusolimogene oderparepvec](https://onco.cc/drugs/vusolimogene-oderparepvec/)
- companies: [Replimune](https://onco.cc/companies/replimune/)

---
JSON: https://onco.cc/api/v1/entities/nct06264180.json